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Samuel Hou2, Michel A Duchosal1*† and Jonathan Back2*†Abstract
Background: CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early
plasma cells, makes it an attractive target for the immunotherapy of B cell malignancies. In this study we present
the generation of a novel humanized anti-CD19 monoclonal antibody (mAb), GBR 401, and investigate its therapeutic
potential on human B cell malignancies.
Methods: GBR 401 was partially defucosylated in order to enhance its cytotoxic function. We analyzed the in vitro
depleting effects of GBR 401 against B cell lines and primary malignant B cells from patients in the presence or in
absence of purified NK cells isolated from healthy donors. In vivo, the antibody dependent cellular cytotoxicity (ADCC)
efficacy of GBR 401 was assessed in a B cell depletion model consisting of SCID mice injected with healthy human
donor PBMC, and a malignant B cell depletion model where SCID mice are xenografted with both primary human
B-CLL tumors and heterologous human NK cells. Furthermore, the anti-tumor activity of GBR 401 was also evaluated in
a xenochimeric mouse model of human Burkitt lymphoma using mice xenografted intravenously with Raji cells.
Pharmacological inhibition tests were used to characterize the mechanism of the cell death induced by GBR 401.
Results: GBR 401 exerts a potent in vitro and in vivo cytotoxic activity against primary samples from patients representing
various B-cell malignancies. GBR 401 elicits a markedly higher level of ADCC on primary malignant B cells when compared
to fucosylated similar mAb and to Rituximab, the current anti-CD20 mAb standard immunotherapeutic treatment for B
cell malignancies, showing killing at 500 times lower concentrations. Of interest, GBR 401 also exhibits a potent direct
killing effect in different malignant B cell lines that involves homotypic aggregation mediated by actin relocalization.
Conclusion: These results contribute to consolidate clinical interest in developing GBR 401 for treatment of
hematopoietic B cell malignancies, particularly for patients refractory to anti-CD20 mAb therapies.
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The last decade has seen an increased interest in the use
of antibody-based therapeutic approaches for cancer
treatment with clear efficacy and safety profiles [1-3]. In
this context, anti-CD20 monoclonal antibodies (mAbs),
such as the first in line Rituximab (RTX), have been used to
target human B cell malignancies, improving the treatment* Correspondence: michel.duchosal@chuv.ch; jonathanb@glenmarkpharma.com
†Equal contributors
1Service and Central Laboratory of Hematology, University Hospital of
Lausanne, Rue du Bugnon 46, 1011- CHUV, Lausanne, Switzerland
2Glenmark Pharmaceuticals S.A, Chemin de la Combeta 5, 2300 La Chaux
de-Fonds, Switzerland
© 2014 Breton et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.of this group of diseases [4,5]. Anti-CD20 mAbs exert their
antitumor activities through various modes of cell death in-
duction including antibody dependent cellular cytotoxicity
(ADCC) [6], complement-dependent cytotoxicity (CDC)
[7] and direct induction of cell death [4]. However, despite
this success, some patients do not respond to this targeted
mAb therapy. Some of the main molecular mechanisms
underlying the resistance to anti-CD20 mAbs are (a) low
expression levels of CD20 (such as in chronic lymphocytic
leukemia-CLL) [8]; (b) down regulation of CD20 expression
during the treatment [9,10]; (c) expression of CD20 tran-
script variants lacking the RTX epitope sequence [11] andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ponent C2 [12]. Developing novel and potent mAbs to cir-
cumvent such drug resistances is of great importance.
An interesting development is to target CD19, a specific
B cell marker, expressed early during pre-B cell ontogeny
and until terminal differentiation into early plasma cells,
with a potential efficacy on a large panel of B cell malig-
nancies [13]. Indeed, the majority of B cell lineage malig-
nancies (more than 90%) express CD19, including notably
non-Hodgkin’s lymphoma, CLL and acute lymphoblastic
leukemia (ALL) [14,15]. Finally, tumor B cells that have
lost the expression of CD20 after anti-CD20 mAb therapy,
maintain the expression of CD19. Given its biology and
broad expression pattern, CD19 represents an attractive
chemotherapeutic target to treat B cell malignancies. Con-
sequently, efforts are now being deployed to develop novel
anti-CD19 mAbs to treat various hematological malignan-
cies and emerging results from preclinical studies are en-
couraging [16-19].
In the past few years, the knowledge of how the Fc
fragment of antibodies can trigger cytotoxic mechanisms
has improved substantially. In particular, glycosylation
analyses have identified fucose residues as negatively in-
fluencing the binding of the Fc to FcγRIIIa. This recep-
tor is expressed by natural killer (NK) cells, neutrophils
and monocytes and is known to trigger ADCC. Anti-
bodies bearing low levels of fucose residues have been
shown to display enhanced ADCC potential [20,21].
Here we describe GBR 401, a partially defucosylated
humanized mAb targeting the domain II of CD19 and
derived from the parental mouse anti human CD19 anti-
body clone FMC63 [19]. Both in vitro and in vivo data
showed that GBR 401 was highly effective at depleting
human malignant B cells mainly via ADCC. It also exhib-
ited a direct killing effect on human B cell malignancies.
Finally, benchmarking done against RTX, demonstrated
a remarkably superior killing capacity of GBR 401. Our
preclinical results suggest GBR 401 to be an efficacious
therapeutic agent for human B lymphoma and leukemia
and warrant further clinical studies of GBR 401 in these
diseases.
Results
GBR 401 is a partially defucosylated mAb
GBR 401 is a mAb with enhanced affinity for FcγRIIIa due
to its low fucose content. The humanization, binding char-
acteristics and engineering performed to produce GBR 401
are described in Skegro et al. (manuscript in preparation).
GBR 401 is produced in a recombinant CHO cell line
allowing the expression of mAbs with a reduced level of
α1-6 fucose linked to the N-acetylglucosamines in the N-
glycan core. The glycosylation of GBR 401 can be seen by
HPLC run (Figure 1) and is compared to its fully fucosy-
lated parent GBR 401(F) antibody. Whereas GBR 401(F)shows a normal CHO glycosylation profile with biantennary
complex N-oligosaccharides G0F, G1F, G1F’ and G2F, GBR
401 shows a high level of defucosylated glycans G0, G1, G1’
and G2 (Figure 1A). The overall defucosylation level of
GBR 401 reaches approximately 50% versus <1% for GBR
401(F) (Figure 1B).
GBR 401 exhibits a potent in vitro ADCC activity on
malignant B cells
Since NK cell-mediated ADCC is important for the ac-
tivity of many mAbs [16,22-24], we first determined the
ADCC activity of GBR 401 in the Burkitt’s lymphoma
cell line Raji, in comparison with GBR 401(F). In agree-
ment with its low fucose content, GBR 401 displayed a
markedly superior ADCC activity compared to the fully
fucosylated variant (Figure 2A and Table 1).
We next evaluated the ADCC potential of GBR 401, in
comparison with RTX, the standard mAb for lymphoma
therapy and herein used as a positive control and reference.
When we tested the ADCC activity on cell lines where
CD19 and CD20 were highly expressed (Raji, Ramos and
SU-DHL-6, Table 1), GBR 401 and RTX showed a com-
parable maximum killing efficacy (Figure 2B). However,
Namalwa cells that express low levels of CD20 (Table 1)
responded solely to GBR 401. Despite similar maximum
killing efficacies, and substantially higher levels of CD20
compared to CD19 (Table 1), GBR 401 demonstrated an
overall 6-10 fold lower EC50 compared to RTX on various
malignant B cells that include Raji, Ramos and SU-DHL-6
cells indicating a better ADCC activity at low doses (Table 1
and Figure 2B). Of interest, we also investigated whether
GBR 401 was able to kill primary malignant cells. To this
end, peripheral blood mononuclear cells (PBMC) from pa-
tients diagnosed with CLL and other types of lymphomas
(mantle cell lymphoma, Waldenström lymphoma, hairy
cell leukemia-variant and post-transplant lymphoprolifera-
tive disorder) were treated with increasing concentrations
of GBR 401 or RTX in the presence of NK cells purified
from two healthy donors. As shown in Figure 2C, GBR 401
showed a strikingly potent in vitro ADCC activity against
B-CLL cells. Indeed, it decreased by 500 fold (P < .001) the
mean EC50 values (ranging between 0.056 and 15.2 ng/mL)
compared with RTX (15-5000 ng/mL). The maximum
killing efficacy of GBR 401 was also significantly super-
ior (P < .001) to that of RTX (Figure 2C). With primary
lymphoma samples, GBR 401 reduced EC50 values (P < .01,
0.05-93 ng/mL) compared with RTX (5-580 ng/mL)
(Figure 2D), even though there was no difference in their
maximum killing efficacy. These results can partially be
explained by the relatively low expression of CD20 in our
CLL samples (Table 1 and Additional file 1: Figure S1),
which is in agreement with literature data [16,25]. How-
ever, CD19 expressions in CLL samples are very low when
compared with our cell lines and are not vastly different
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Figure 1 Fucosylated and non-fucosylated complex N-glycans analysis for GBR 401 and GBR 401(F). A/ Fucosylated and non-fucosylated
complex N-glycans associated with GBR 401 and GBR 401(F) antibodies analyzed by CE. B/ Diagram of quantitative data with the total level of
defucoylation defined as the sum of G0, G1, G1’ and G2.
Breton et al. Journal of Hematology & Oncology 2014, 7:33 Page 3 of 13
http://www.jhoonline.org/content/7/1/33from those of CD20 (Table 1 and Additional file 1: Figure
S1) [25]. Similarly, CD20 levels on lymphoma cells have
been reported to be higher than CD19 levels [25]. These
observations indicate that the better activity of GBR 401
on CLL and lymphoma samples cannot be solely ex-
plained by a bias in CD19 levels but rather by a better
cytotoxic activity.
Taken together, these data demonstrate that GBR 401
displays potent ADCC activity against various cell lines
and primary CLL and lymphoma samples. Interestingly,
GBR 401 shows far superior ADCC potential over RTX in
settings where CD20 expression is reduced as is seen in
some CLL samples and in Namalwa cells. This indicates
that GBR 401 could be an interesting alternative therapeutic
agent in such conditions where RTX is poorly effective.
GBR 401 is highly efficient at depleting B cells in
xenografted SCID mice
The promising in vitro ADCC potential of GBR 401
prompted us to investigate its in vivo efficacy. Given the
lack of cross reactivity of GBR 401 to relevant non-human
species (unpublished data) it was not possible to test the
toxicological effect of GBR 401 in a classical animal model.
Human tumor cells xenografted into immunodeficient
mice are commonly used to assess the efficacy of oncology
drugs on human target cells. We therefore evaluated the
efficacy of GBR 401 in a SCID mouse model irradiated todeplete murine NK cells (to increase human cell engraft-
ment), and repopulated with human PBMCs. These latter
cells provide both the human B cell targets as well as hu-
man effector cells (NK cells and monocytes), and hence
this model is expected to display all the potential depletion
mechanisms that could occur in humans (Figure 3A). GBR
401 demonstrated a clear dose response for B cell deple-
tion, with an EC50 value of 0.03 mg/kg and a maximum
efficacy from 2 mg/kg with 84% reduction of the B cell
population 4 days after mAb treatment. In comparison, the
dose at which RTX lost efficacy (0.1 mg/kg) was at least 5
fold higher than GBR 401 (0.02 mg/kg) despite their simi-
lar efficacies at the dose of 2 mg/kg.
The efficacy of GBR 401 in killing normal B cells is of
clinical interest in the potential to deplete primary malig-
nant B cells from patients. To test this issue, SCID mice
were co-injected intra-peritoneally with B-CLL from pa-
tients and heterologous NK cells from healthy donors, at a
ratio of one NK cell for six CLL cells (Figure 3B). This NK
cell supplementation aimed at mimicking the presence of
tissue NK cells that would be present in the organs of CLL
patients, but that are at very low levels in PBMC. Com-
pared to mice treated with the isotype control (herceptin®,
HER), mice that received GBR 401 at a single dose of
2 mg/kg displayed a dramatic and significant reduction
(92%) of B-CLL cells in the peritoneal cavity after seven
days (P < .001). At the same dose RTX exhibited similar
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Figure 2 B leukemia cells are sensitive to GBR 401 mediated ADCC in vitro. A/ Raji cells (Burkitt’s lymphomas, CD19+ CD20+), were incubated
during 4 hr with 0.5 μg/mL of mAbs in the presence of purified NK cells from random donors (effector/target ratio of 5). Target cell death was
measured by LDH release. Specific ADCC (%) was calculated by the formula: (Sample release – spontaneous release)/(Max release – spontaneous
release) x100. The graph shows the average specific ADCC (%) ± SD of triplicates obtained with one NK cell donor representative of several different
donors. The Table 1 presents the data summary for all donors. GBR 401(F) is the fully fucosylated variant of GBR 401. B/ cell lines Raji, Ramos (Burkitt’s
lymphomas, CD19+ CD20+), Namalwa (Burkitt’s lymphoma, CD19+ CD20low) and SU-DHL-6 (Human diffuse histiocytic lymphoma, CD19+ CD20+) were
incubated during 4 hr with various concentration of mAbs in the presence of purified NK cells from random donors (effector/target ratio of 5). Target
cell death was measured as in (A). The graphs show the average specific ADCC (%) ± SD of triplicates. Each graph shows a representative result obtained
from at least four different NK cell donors. The Table 1 presents the data summary for all donors. C + D/ PBMC from patients with CLL (n = 13) (C) or B
cell lymphomas (n = 4) (D) were incubated with peripheral blood NK cells (effectors/target ratio of 1) from two different healthy volunteer donors with
various concentration of mAbs (0.005 ng/mL - 5 μg/mL) for 24 hr. HER was used as control mAb. The malignant B cells were stained for cell death by
7AAD and analyzed by flow cytometry. Figures show EC50 values and maximum killing percentage of specific ADCC for each NK donor and leukemia
sample combination.
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evaluated the anti-tumor activity of GBR 401 in a dis-
seminated lymphoma model in which human Raji cells
expressing high levels of CD19 were injected intraven-
ously into SCID mice and GBR 401 administered as de-
scribed in the “Materials and Methods”. In this model,
Raji cells invade all mouse organs including the central
nervous system and mimic diseases such as disseminated
Burkitt’s lymphoma and ALL. GBR 401 treatment signifi-
cantly prolonged mice survival by 2.1 fold (P < .01), com-
pared with animals injected with vehicle or control mAb
HER (Figure 3C). The median survival time was 51 daysfor the GBR 401-treated mice compared with 24 days for
the control antibody HER or PBS-treated ones.
Collectively, these data demonstrate the capacity of
GBR 401 to deplete malignant B cells and prolong mice
survival in multiple SCID mouse models.
CDC is not involved in GBR 401 mediated cell death
To further characterize the cell death mechanisms under-
lying the antitumor activity of GBR 401, we investigated
whether CDC could be involved in GBR 401-mediated cell
death. CDC is another potential mechanism of action of
mAbs and plays a major role in the efficacy of RTX
Table 1 Summary of mean ABC (antibody binding capacity) values and ADCC activities of GBR 401 and RTX on primary
B malignancies and B cell lines
Target
cells
Antigenic
CD19 sites
Antigenic
CD20 sites
EC50 GBR
401 (μg/ml)
EC50 RTX
(μg/ml)
EC50 GBR 401
(F) (μg/ml)
Average max
killing GBR 401 (%)
Average max
killing RTX (%)
Average max
killing GBR 401
(F) (%)
Raji 57 100 (11 000) 100 400 (13 200) 0.0012 0.012# 0.08# 80 60 30#
Ramos 50 700 (6700) 160 600 (29 700) 0.0009 0.016 60 60
SU-DHL-6 30 000 (4800) 822 400 (41 000) 0.0008 0.0045 50 40
Namalwa 37 900 (4500) 1 700 (1200) 0.002 NA 60 15
B-CLL 10 520 (4140) 3 230 (2000) 0.0016 (0.003) 0.8*** (1.1) 60.04 (16.9) 44.54*** (15.1)
Lymphoma 0.015 0.15** 32 32
The table displays ADCC values obtained with at least 4 different NK cell donors for Raji, Ramos, SU-DHL-6 and Namalwa cells. The EC50 values are given in μg/mL
(SD). The average max killing is given in % (SD). Antigenic CD19 and CD20 sites values are mean (SD). NA, Not applicable. Stars or # indicate statistical significance
compared to GBR 401 value (*< .05, **< .01, ***< .001 by student t test, #< .05 by Wilcoxon ranked test).
Figure 3 GBR 401 can deplete B cells in xenografted SCID mice. A/ SCID mice were irradiated, reconstituted with human PBMCs and treated
with mAbs. Depletion of human B cells was monitored 4 days after antibody treatment by quantifying the proportion of total human B cells in
the spleen. The graph shows pooled data from two independent studies. HER isotype control was dosed at 10 mg/kg and 2 mg/kg. B/ Patient
derived CLL (n = 5) (15×106) were injected i.p. in SCID mice simultaneously with purified NK cells from healthy donors (effectors/target ratio of 6)
and mAb treatment (2 mg/kg). The mice were sacrificed seven days later and cell death was analyzed on peritoneal CLL cells (CD45 + CD5 + CD3-).
The graph shows the absolute alive B-CLL cell number found in the peritoneal cavity. C/ Groups of 6 SCID mice were injected i.v. with 2 × 105 Raji cells
(day 0). Mice were treated with mAbs (GBR 401, HER, 2 mg/kg) or PBS alone at day three, seven and ten, and monitored daily and sacrificed when hind
leg paralysis or signs of illness appeared. All control groups died within 24 days after Raji injection while GBR 401 increased median survival by 2.1
fold (P < .01).
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http://www.jhoonline.org/content/7/1/33[26,27]. As expected, the addition of complement to the
in vitro cultures allowed RTX to significantly increase
cell death, whereas GBR 401 was unable to trigger CDC
on Raji cells (Additional file 2: Figure S2). However, this
inability to trigger CDC is not a characteristic specific
to GBR 401 as numerous other anti-CD19 cytotoxic
mAbs in development are reported to lack CDC activity
[17,28-30].
GBR 401 induces direct cell death and inhibits the
clonogenic capacity of malignant B cells
Direct induction of cell death is a process described for
mAbs engaging CD19 or CD20 [18,29,31-34]. The induc-
tion of cell death by GBR 401 on various human B lym-
phoma cells was therefore evaluated in vitro using flow
cytometry and annexinV/7AAD staining. A short time-
exposure (2 hrs) of GBR 401 to Mec-1, Raji and SU-DHL-6
cell lines resulted in a rapid increase in the proportion of
late apoptotic/necrotic dead (annexinV + 7AAD+/annexin-AnnexinV
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Figure 4 GBR 401 induces homotypic adhesion and cell death in vitro
(0.1 ng/mL – 5 μg/mL) for 2 hours. A/ Cell death was measured in flow cyt
of at least three independent experiments (mAbs at a concentration of 1 μg/m
annexinV + 7AAD+, annexinV-7AAD+). The graphs show the percentage of dea
mAb incubation was assessed with CountBright™ Absolute Counting Beads. The
counted by flow cytometry experiment. C/ The clonogenic capacities of Raji an
with the mAbs (1 μg/mL) for 2 hours and plated on methylcellulose medium c
counted under an inverted microscope. The graph shows the mean +/- SD of t7AAD+) or early apoptotic dead (annexinV + 7AAD-) cells
with maximum killing effects of 70-80% when compared to
the isotype control HER (Figure 4A). The direct killing
effect on these malignant B cells was variable; Mec-1
being less to moderately sensitive, whereas Raji and
SU-DHL-6 were highly sensitive to GBR 401 treatment,
suggesting a cell based specificity for direct cell death
induction. The effect of RTX on these three cell lines was
very weak, indicating a selective mechanism of rapid cell
death induction on malignant lymphoid B cells by GBR 401
(Figure 4A). To provide additional evidence for direct cyto-
toxicity of GBR 401 on malignant B cells, the absolute B
cell number was quantified after mAb treatments. In agree-
ment with annexinV and 7AAD staining data, GBR 401
was much more potent than RTX at reducing the number
of malignant B cells after drug exposition (Figure 4B). To
further demonstrate the tumor growth inhibitory effects of
GBR 401 (in comparison with RTX) we evaluated the ca-
pacity of malignant B cells treated with these mAbs to formSU-DHL-6Raji
C
Mec-1
Raji
SU-DHL-6
B
og mAb concentration ( /mL)
. Raji, SU-DHL-6 and Mec-1 cell lines were incubated with mAbs
ometry by annexinV/7AAD. Flow cytometry panels are representative
L) and numbers indicate the percentage of dead cells (annexinV + 7AAD-,
d cell +/- SD of three independent experiments. B/ Cell depletion after
graphs represent the absolute alive cell number +/- SD (annexinV-7AAD-)
d SU-DH-L6 cell lines were assessed with CFU assays. 500 cells were treated
ontaining proliferation factors. Fourteen days later, the colonies were
hree independent experiments.
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in Figure 4C, GBR 401 substantially decreased the CFU ac-
tivity (P < .001) compared to RTX on Raji and SU-DHL-6
cells after 14 days.
Collectively, these data support a direct cytotoxicity
potential for GBR 401 and highlight its potent killing ef-
fects on malignant B cells.
GBR 401-mediated cell death requires actin
reorganization
To elucidate the molecular mechanisms underlying GBR
401-mediated cell death, we first sought to identify the
cell death program involved in this process. GBR 401-
treated malignant B cells underwent phosphatidylserine
externalization, as evidenced by annexinV staining, sug-
gesting apoptotic cell death. To determine whether cas-
pase activation was involved, Raji cells were pre-incubated
with two broad spectrum caspase inhibitors (QVD and
zVAD), prior to GBR 401 exposition. As shown in Figure 5,
none of the inhibitors attenuated GBR 401-induced cell
death, supporting a caspase-independent pathway. We
next investigated whether autophagy could be implicated
in this process. Autophagy is normally a cytoprotective
mechanism, but in some stressed conditions, it has the
capacity to induce cell death [35]. To test this, Raji cells
were pre-incubated with different autophagic inhibitors
including a blocker of autophagosome formation (3MA)Figure 5 GBR401 does not trigger apoptosis and autophagy.
Raji cells were pre-incubated with inhibitors of caspases (QVD,
ZVAD), of lysosomal proteases (Chloroquine, Bafilomycin A), or of
autophagosome formation (3MA) and were treated with mAbs
(1 μg/mL) for 2 hours. Absolute alive cell numbers +/- SD and cell
death +/- SD were then measured by CountBright™ Absolute Counting
Beads and annexinV/7AAD flow cytometry staining.and inhibitors of lysosomes (Bafilomycin A and Chloro-
quine), and subsequently treated with GBR 401. None of
these inhibitors could prevent GBR 401-killing effects
(Figure 5), ruling out any link between GBR 401-induced
cytotoxicity and lysosome permeabilization, a cell feature
most often associated with mAb-induced cell death [36,37].
We also excluded the involvement of reactive oxygen
species (ROS) production, massive internalization of
CD19, mRNA transcription, and new protein synthesis
in GBR 401-induced direct cytotoxicity (Additional file 3:
Figure S3).
Homotypic aggregation is a particular cell process that
has been reported to be associated with mAb-induced
cell death [33,34,38]. We then assessed whether homoty-
pic aggregation could be involved in this killing process.
To address this issue, Raji cells were treated with GBR 401
or RTX, and subsequently cell adhesion was visualized
using light microscopy. As shown in Figure 6A (no treat-
ment condition), GBR 401 induced a rapid and strong
homotypic aggregation on Raji cells whereas RTX treat-
ment generated little aggregation. This observation suggests
a correlation between homotypic aggregation and GBR
401-induced cell death. Actin reorganization has been re-
ported to play a key role in homotypic aggregation and cell
death [39,40]. To examine whether actin reorganization is
required in GBR 401-mediated direct cytotoxicity, various
malignant B cells were treated with GBR 401 or RTX in
the presence or absence of latrunculin B, an inhibitor of
actin polymerization. As expected, latrunculin B fully
prevented the homotypic aggregation induced by these
mAbs (Figure 6A). Importantly, the blockage of homo-
typic cell adhesion by latrunculin B was associated with
a loss of direct cytotoxicity induced by GBR 401 and RTX,
as revealed by annexinV/7AAD staining (Figure 6B). Simi-
larly, the absolute cell number and the CFU counts were
equivalent between the HER control treated cells and
GBR 401-treated ones in the presence of latrunculin B
(Figure 6B and C). To further clarify the involvement of
actin cytoskeleton reorganization in cell death induction
after GBR 401 exposure, immuno-fluorescence labeling of
actin was performed on treated-Raji cells. As shown in
Figure 6D, we observed an important redistribution of
actin at the cell-cell contact zones in GBR 401-treated
cells. In contrast, RTX was not able to induce this massive
relocalization. In accordance with the data mentioned
above, latrunculin B prevented the polymerization of actin
and its relocalization induced by GBR 401 (Figure 6D),
indicating that actin integrity and reorganization are
required for GBR 401-induced cell death.
Altogether these results indicate that the ligation of
GBR 401 on B cells induces a homotypic cell aggregation
through actin cytoskeleton mobilization and relocaliza-
tion at the cell-cell synapse, which leads to the induction
of non canonical apoptotic pathways.
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Figure 6 Cell death induced by GBR401 is dependent on homotypic adhesion and on actin microfilament reorganization. Mec-1, Raji
and SU-DHL-6 cells were pre-incubated with the inhibitor of actin polymerization latrunculin B and treated with mAbs (1 μg/mL) during 2 hours.
A/ Homotypic adhesion was assessed by light microscopy (original magnification x20). Raji cells are shown as a representative example. B/ Cell
death and absolute alive cell number were analyzed by annexinV/7AAD flow cytometry staining. C/ The clonogenic capacities of Raji and SU-
DHL-6 cells were assessed with CFU assays. D/ Raji cells were sedimented onto microscope slides. After fixation with 4% paraformaldehyde in
PBS, cells were permeabilized, stained with Phalloïdin-A488 and analyzed by fluorescent microscopy (scale bar: 10 μm). All the measurements
were realized in triplicates and the graphs represent mean values +/- SD.
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B cell depletion therapy using mAbs alone or in combin-
ation with chemotherapeutic drugs has greatly improved
the treatment of various hematological malignancies and
prolonged overall patient survival [41]. Anti-CD20 mAbs,
notably RTX, however, may induce resistance in patients
[42] and alternative strategies are needed. GBR 401, a
novel glyco-engineered and humanized anti-CD19 mAb,
another B-cell-specific cell surface antigen, is a potential
complementary to anti-B cell mAbs. Indeed, we demon-
strate in the present study that GBR 401 exerts a potent
in vitro and in vivo cytotoxic activity on malignant cells
derived from cell lines and from patients diagnosed with
various B cell malignancies.
ADCC is a major mechanism of cell death triggered by
mAbs. Moreover, several studies have demonstrated an
enhancement of ADCC activity of mAbs due to fucose de-
pletion in the Fc region N-linked glycans [43-47], resultingin a higher binding affinity toward FcγRIIIa. In agreement,
GBR 401 exhibited an increased ADCC activity on primary
malignant B cells. Strikingly, we observed a substantial dif-
ference in the ADCC efficacy of GBR 401 between B-CLL
and lymphoma samples (Figures 2C and D) even though
lymphoma and CLL samples are reported to express simi-
lar amounts of CD19 [25]. In addition we did not observe
a correlation between the killing efficiency of GBR 401
and CD19 levels on CLL samples (Additional file 2: Figure
S2). These observations suggest that the global efficacy
of GBR 401 may depend on the intrinsic characteristics
of the malignant B cell rather than, or in addition to, the
level of CD19 expression. This is in agreement with the
fact that GBR 401 is able to trigger ADCC at very low
concentrations, when engaging a small number of CD19
molecules. This property to induce B cell depletion by en-
gaging a very low number of receptors on target cells
might be crucial to achieve efficacy in patients where the
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GBR 401 efficiently depleted malignant CD19+ B cells ex-
pressing low levels of CD20 (such as primary B-CLL and
Namalwa cells) which are poorly affected by anti-CD20
mAb treatment. This was reflected in a stark 500 fold bet-
ter EC50 for GBR 401 compared to RTX on primary CLL
cells. Interestingly, while the MEDI-551 anti-CD19 anti-
body also showed better killing on a limited number of
primary CLL samples, the difference with RTX was not as
marked as with GBR 401 [16]. We could not compare kill-
ing efficacies of GBR 401 to other anti-CD19 or defucosy-
lated anti-CD20 mAb currently in development, since
none of them were commercially available at the time of
realization of our experiments. The comparison of GBR
401 and defucosylated anti-CD20 antibodies will provide
essential data on the efficiencies of CD19 and CD20 tar-
geting in various B-cell malignancies. Nevertheless our
data support the high efficacy of targeting CD19.
These observations underline that patients with B-CLL
could benefit from GBR 401 treatment and also strengthen
the rationale of developing anti-CD19 mAb therapy as an
alternative or complementary strategy to circumvent the
resistance to, or the failure of, anti-CD20 mAb therapies
associated with low levels of CD20 expression, downregu-
lation or expression of CD20 transcript variants [48].
GBR 401 does not trigger CDC on malignant B cells, a
common feature of anti-CD19 mAbs in development
[28-30]. However, we found by various readouts, includ-
ing flow cytometry using annexinV/7AAD staining, cell
count number and clonogenic assay, that GBR 401 is
highly effective at inducing direct cell death (i.e. without
the requirement of Fc-mediated mechanisms) in malig-
nant B cells. GBR 401-induced direct cell death was con-
firmed in a xenochimeric SCID mouse model, in which
GBR 401 treatment significantly prolonged overall sur-
vival in mice bearing human lymphoma when compared
with xenochimeric mice injected with isotypic Ig. As ex-
pected in this experiment, RTX also prolonged xenochi-
meric mouse survival even to a greater extent than GBR
401 (data not shown). This model lacks the human ef-
fector cell component and thereby did not evoke the full
ADCC potential of GBR 401, while RTX still benefited
from CDC and to a greater extent, compared to GBR
401, from ADCC triggered by mouse effector cells (our
unpublished data). However, the contribution of murine
macrophages in the protective effect of GBR 401 could
not be excluded. Indeed, in previous studies using other
anti-CD19 mAbs with increased binding affinity toward
FcγRIIIa, it was clearly demonstrated that murine macro-
phages (but not NK or neutrophils) were involved in the
in vivo B cell depletion [28]. The contribution of macro-
phages or direct cell death in the GBR 401 protective effect
in mice bearing human lymphoma remains to be further
clarified.Our study also provides some insights into the molecu-
lar mechanisms involved in the direct cell death evoked by
GBR 401. We showed that GBR 401-induced direct cell
death did not involve autophagy, caspase activation or
lysosomal permeabilization but strongly correlated with
homotypic aggregation mediated by the relocalization of
actin toward the cell-cell interface. These observations are
consistent with previous studies, showing that the actin
cytoskeleton was playing a key role in the cell death in-
duced by various mAbs [34,38,40,49].
In conclusion, we demonstrated that GBR 401, a defu-
cosylated humanized anti-CD19 mAb, can induce ADCC
and direct-cell death on both normal B cells and malig-
nant B cell lines but more importantly on primary B cell
malignancies. All studies were benchmarked against RTX,
the current anti-CD20 mAb standard immunotherapeutic
treatment for B cell malignancies, and demonstrated high
killing capacities for GBR 401. This study contributes to
consolidate clinical interest in developing anti-CD19 mAbs
for the treatment of hematopoietic B cell malignancies,
particularly for patients resistant or refractory to anti-
CD20 mAb therapy or relapsing after such treatment.
Materials & methods
Cell lines, primary cells and culture conditions
Raji, Ramos, Namalwa (human Burkitt’s lymphoma cell
lines), SU-DHL-6 (human diffuse histiocytic lymphoma
cell line) and Mec-1 (human B-CLL cell line) were ob-
tained from the German Collection of Microorganisms
and Cell Cultures (DSMZ, Germany) or the American
Type Culture collection (ATCC, USA). NK cells and per-
ipheral blood mononuclear cells (PBMC) were isolated
from fresh buffy coat layers from healthy donors (Lausanne
Blood Transfusion Centre). PBMC were purified after Ficoll
gradient centrifugation (Histopaque®-1077 Sigma-Aldrich).
To obtain NK cells, PBMC were enriched in CD56+ cells
using MACS separation with MicroBeads (Miltenyi Biotec).
Purity of NK cells (between 80% and 95%) was assessed by
flow cytometry.
Bone marrow or PBMC cells from 22 patients with CLL
or B cell lymphomas were collected after human ethical
committee approval from our institution. Cells were culti-
vated in RPMI (Gibco) with 10% heat-inactivated fetal calf
serum (FCS, Gibco), 100 U/mL penicillin and 100 μg/mL
streptomycin (Bioconcept) at 37°C, 5% CO2. Study proto-
col (reference 295/11) was approved by the ethics com-
mittee at the University of Lausanne.
Mice
SCID mice (8 weeks old) were purchased from Iffa
Credo (L’Arbresle, France) and maintained under specific
pathogen-free conditions within the animal facilities at the
University Hospital of Lausanne. The mice were handled in
accordance with institutional regulations after approval of
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Manipulations were performed under a laminar flow hood
under sterile conditions.
Monoclonal antibodies and carbohydrate analysis
GBR 401 was obtained from Glenmark Pharmaceuticals
S.A. The analysis of the carbohydrates associated with
GBR 401 and with the fucosylated form GBR 401(F) was
performed by capillary electrophoresis (CE) using a PA
800 analysis system with a 488 nm Laser Module and a
LIF detector (Beckman Coulter Inc). The separation was
achieved with an N-CHO coated capillary, all buffer and
labeling reagents were obtained from the Carbohydrate
Labeling and Analysis Kit from Beckman Coulter.
The isotype-matched control herceptin® (HER) and ri-
tuximab® (RTX) were the clinical products.
Flow cytometry
Anti hCD45-FITC, hCD3-ECD, hCD5-PECy7, hCD20-ECD
and hCD19-PECy7 were purchased from Immunotech.
Anti hCD56-PE was purchased from Becton Dickinson
Biosciences Pharmingen. FACS analysis was performed
on a Beckman Coulter Cytomics FC500 flow cytometer
and data were analyzed with the Kaluza Version 1.1 soft-
ware (Beckman Coulter). Expression levels of CD19 and
CD20 were determined using QIFIKIT flow cytometry
(Dako) according to the manufacturer instruction. Mouse
anti hCD19 (clone HIB19, eBioscience) and hCD20 (clone
B9E9, Becton Dickinson Biosciences Pharmingen) were
used as primary antibodies.
Cell death induction and inhibition
Cells were incubated 2 hours with mAbs (HER, GBR
401 or RTX, 1 μg/mL). Cell death inhibitors were pre-
incubated 1 hour before adding mAbs. 3-Methyladenine
(3-MA, 10 mM), Q-VD-OPh (QVD, 50 μM), Chloro-
quine (100 μM) and Bafilomycin A (50nM) were pur-
chased from Sigma-Aldrich. ZVAD-fmk (ZVAD, 100 μM)
was purchased from BachemAG. Latrunculin B (20 μM)
was purchased from Calbiochem. Cell death was assessed
using AnnexinV-FITC (eBioscience) and 7AAD (Beckman
Coulter) staining. Absolute cell number was characterized
with CountBright™ absolute counting beads (Molecular
Probes).
Detection of cellular and mitochondrial reactive oxygen
species (ROS)
The intracellular reactive oxygen species H2O2 level was
measured using 5-(and-6)-carboxy-2',7'-dichlorodihydro-
fluorescein diacetate (Carboxy-H2DCFDA, Molecular
Probes). Briefly, the cell-permeable molecule becomes
green-fluorescent when oxidized with intracellular H2O2.
Cells were incubated during 30min at 37°C with 7μM
Carboxy-H2DCFDA and green fluorescence was measuredon flow cytometry. The mitochondrial superoxides were
measured with MitoSOX™ Red Mitochondrial Superoxide
Indicator (Molecular Probes). The molecule selectively tar-
gets mitochondria, and becomes red-fluorescent when oxi-
dized with superoxide specifically. Cells were incubated
during 30min at 37°C with 5μM MitoSOX in PBS with Ca/
Mg and red fluorescence was measured on flow cytometry.
The ROS scavenger Tiron (5mM), the protein synthesis in-
hibitor Cycloheximide (50μM), the mRNA transcription
inhibitor Actinomycine D (5μM) and the endocytosis in-
hibitor Dynasore (50μM) were purchased from Sigma-
Aldrich (St Louis, MO).ADCC experiments
Target cells were stained with mAbs (HER, GBR 401 or
RTX) for 15 minutes (concentrations between 0.005 ng/
mL and 5 μg/mL). NK cells, activated by incubation with
IL-2 (100 U/mL) during 16 hours, were added at a ratio
NK cells/target cells of 1/1 (experiments on primary cells)
or 5/1 (experiments on cell lines) and were incubated for
4-24 hours at 37°C. ADCC efficacy was analyzed by cytom-
etry (experiments on primary cells) by quantifying the ab-
solute number of living target cells after incubation. CLL
cells were identified as CD3-CD5+, B lymphoma cells as
CD19 + CD20+ cells, NK cells were CD3-CD56+ and dead
cells were 7AAD+. ADCC was also determined by LDH re-
lease (experiments on cell lines) using the CytoTox96 kit
(Promega) according to manufacturer’s instructions. Spe-
cific ADCC was determined by subtracting specific effect
induced by mAbs to specific effect induced by NK cells
and control mAb HER.CDC experiments
Endogenous CD19-expressing tumor cells (Raji) were
harvested and washed once with 1× PBS. Baby rabbit
complement (Harlan) was reconstituted with sterile water
according to the manufacturer’s instructions. Cells were
incubated with 2.5% baby rabbit complement in culture
medium for 3 hr at 37°C. The cellular mortality was quan-
tified with the Cytotox 96 non radioactive cytotoxicity
assay (Promega), according to the manufacturer’s instruc-
tions. This assay quantifies the LDH release by dead cells
via a colorimetric enzymatic reaction. OD readings trans-
late to the quantity of LDH released and therefore cell
mortality. Percent cytotoxicity was calculated as follows.
First, the background signal measured in wells containing
only medium was subtracted to all other values. The for-
mula was: Specific CDC (%) = [(SpR-SR)/(MR – SR)] ×100,
where SpR corresponds to the LDH release measured in a
sample. SR corresponds to the spontaneous LDH release
measured for target cells alone. MR corresponds to the
maximum release measured for target cells submitted to 3
freeze/thaw cycles.
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For primary CLL cell depletion, NK cells (ratio NK cells/
target cells of 1/6) and mAbs (2 mg/kg) were injected
simultaneously into the peritonea of SCID mice. Seven
days after injection, animals were euthanized and treat-
ment efficacy was analyzed by determining the number
of human B cells (CD45 + CD19 + CD20+) in the peri-
toneal cavity of mice. For the healthy donor PBMC de-
pletion, SCID mice were sub-lethally irradiated at day 0,
depleted for murine NK cells using the TMbeta-1 anti-
body (mCD122 antigen, BioXCell, USA) on day 1 and 8,
and injected with 30 × 106 human PBMC on day 3. Animals
were treated with mAbs at day 14 (single bolus injection)
and sacrificed at day 18. The spleens were analyzed by flow
cytometry to determine the proportion of human B cells
in human CD45+ population. Total human B cells were
identified as the sum of CD19+ CD20-, CD19+ CD20+
and CD19- CD20+ populations. For the xenograft model
of Raji, cells (2 × 105 cells) were injected intravenously in
SCID mice. Animals were divided into three groups that
received GBR 401 (2 mg/kg, n = 6), HER (2 mg/kg, n = 6),
or saline (n = 6) at days 3, 7 and 10. Animals were moni-
tored daily for signs of illness and killed if hind limb par-
alysis was noted.
Light microscopy and immunofluorescence imaging
Raji cells were pre-incubated 1 hour with latrunculin B
(20 μM) and treated 2 hours at 37°C with mAbs (1 μg/
mL) in flat-bottomed 24-well plates. Cell aggregation
was assessed in light microscopy using the Leica DM IL
inverted microscope at the original magnification ×20.
For immunofluorescence, cells were fixed in paraformal-
dehyde 4%, sedimented onto SuperFrost slides (Menzel-
Glaser), permeabilized in 0.1% Triton X-100 and stained
with Alexa488-Phalloidin (Molecular Probes). Slides were
mounted in FluorSave reagent (Calbiochem), and acquired
on an Axioplan 2 fluorescent microscope (Zeiss).
Clonogenic assays
Raji and SU-DHL-6 cell lines were treated 2 hours with
mAbs (1 μg/mL) and evaluated for their capacity to form
colonies. 500 treated cells were plated in 1 mL semi-
solid methylcellulose medium (Methocult GF +H4435,
StemCell Technologies). Colonies (>50 cells) were scored
under an inverted microscope after 14 days at 37°C with
5% CO2.
Statistics
Data were expressed as mean plus or minus standard de-
viation (SD). Student’s t-tests or Wilcoxon ranked tests
were performed to determine differences between sam-
ples. GraphPad Prism version 6.02 (GraphPad Software,
San Diego, CA) was used for statistical analysis. P valuesinferior to .05 were considered statistically significant
(* < .05, ** < .01, *** < .001).
Additional files
Additional file 1: Figure S1. In vitro ADCC efficacy for GBR 401 is not
related to antigen expression. A/ CD19 and CD20 site numbers of patient
derived CLL cells (n = 5) were calculated according to Qifikit protocol as
described in materials & methods. B/ PBMC from patients with CLL (n = 5)
were incubated with peripheral blood NK cells (effectors/target ratio of 1)
from two different healthy volunteer donors with various concentration of
mAbs (0.005 ng/mL - 5 μg/mL) for 24 hr. HER was used as control mAb. The
malignant B cells were stained for cell death by 7AAD and analyzed by flow
cytometry. Figures show the average specific ADCC (%) ± SD of three repre-
sentative CLL samples with one NK cell donor. C/ Figures show EC50 values
and maximum killing percentage of specific ADCC versus the antigenic site
number of CD19 or CD20 for all patient derived CLL cells tested (n = 5).
Additional file 2: Figure S2. GBR 401 does not trigger complement-
dependent cytotoxicity Standard CDC assays were performed incubating
Raji cells with mAbs (1 μg/mL) and 2.5% baby rabbit complement. The
isotype control was Herceptin. The graph shows the mean specific
cytotoxicity (%) +/- SD of triplicates.
Additional file 3: Figure S3. GBR 401 cell death is not induced by ROS
production, CD19 internalization or by mRNA and protein syntheses.
A/ Raji cells were pre-incubated with the ROS scavenger Tiron and were
treated for 2 hours with mAbs (1 μg/mL). Cell death (annexinV + 7AAD+/-),
intracellular H2O2 (Carboxy- H2DCFDA) and mitochondrial superoxide (Mito-
sox) were assessed by flow cytometry. B/ Raji cells were pre-incubated with
inhibitors of endocytosis (Dynasore), mRNA transcription (Actinomycin D) or
protein synthesis (Cycloheximide) and were treated for 2 hours with mAbs
(1 μg/mL). Cell death (annexinV + 7AAD+/-) was assessed by flow cytometry.
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